Press Release

JP Selecta, Global Good Collaboration Brings Novel Microbiology Incubator to Market

December 17, 2018 Barcelona, Spain

Microbiologists now have ability to adequately conduct microbiological tests in laboratories with unreliable access to power.

Intellectual Ventures’ Global Good fund signed a licensing agreement with J.P. Selecta to manufacture and distribute a microbiological incubator for laboratories in low-resource settings.

“This incubator will help frontline health workers perform important culture-based microbiological tests in places where power is unreliable – a critical step in managing diseases like tuberculosis, sepsis, enteric and diarrheal diseases, and sexually-transmitted bacterial infections,” said Maurizio Vecchione, Executive Vice President of Global Good.

Accurate detection and surveillance of some infectious diseases involves studying bacteria by growing it in devices that maintain optimal temperature and other atmospheric conditions. High unit costs, frequent power outages, lack of adequate temperature monitoring and ambient temperature control, and high maintenance requirements associated with currently available microbiological incubators have severely limited their usage and effectiveness in low-resource laboratories.

The INCUDIGIT-SV 30 can operate without a reliable power supply or ambient climate control capabilities. Its internal sample chamber compartment capacity is 31 liters to support the need of a mid-sized microbiology laboratory. It has removable, adjustable shelves; an optional temperature data logging system; a user-adjustable temperature setpoint of 35°C, 36° C or 37° C; and a LED temperature display.

"From the first moment we were presented, in 2016, with the new microbiology incubator project by Global Good we were excited about the project. For many laboratories or health centers with low resources and deficient electrical power supplies, having a culture incubator such as the INCUDIGIT-SV 30 provides the opportunity to perform microbiological cultures, obtaining diagnoses in shorter time period, and in the process saving lives," said José Antonio Ejarque, Commercial Director of JP Selecta.

About Intellectual Ventures’ Global Good Fund

Global Good is dedicated to inventing technology for humanitarian impact. Millions of people suffer and die each year in poor countries from causes that humanity has the scientific and technical ability to solve. Funded by Bill Gates and focused on a shared vision with Nathan Myhrvold, Global Good invents technology to solve some of humanity's most daunting problems. Global Good does this by collaborating with leading humanitarian organizations, forward-looking governments, research institutions, and corporate and private sector partners that bring our inventions to market. www.globalgood.com  

About J.P. Selecta

JP Selecta is a family owned company which was founded in 1950 by Mr. Joaquim Puig.  The mission of the company is to satisfy the materials and laboratory equipment needs of laboratories.

Mr. Jordi Puig is the General Director, who directs THE SELECTA GROUP. www.grupo-selecta.com/en

The SELECTA group consists of three companies:

J.P. SELECTA, S.A.U. – Designs and manufactures laboratory equipment

COMECTA, S.A.U. – Laboratory equipment wholesaler

AQUISEL, S.L. – Specializes in the manufacturing of disposable blood sample collection products

More Buzz From IV

Advancing Diversity, Equity, and Inclusion at IV

Learn more about DEI at IV.

Read More
Bloomberg Businessweek’s “Hello World” Meets Nathan Myhrvold

Nathan Myhrvold is the subject of the latest "Hello World" episode.

Read More
IV Announces New Licensing Agreement to its Invention Investment Fund Portfolio

IIF off to a strong start in 2023.

Read More
We use cookies on this website to enhance your browser experience and to analyze your traffic. To learn more about cookies and how we use them view our cookie policy. By continuing to use our website you consent to the use of cookies.